Lactoferrin Efficacy Versus Ferrous Sulfate in Treatment of Patients With Iron Deficiency Anemia
1 other identifier
interventional
96
1 country
1
Brief Summary
Lactoferrin (Lf) is a mammalian cationic iron binding glycoprotein belonging to the transferrin family which was discovered 70 years ago, and isolated simultaneously from human and bovine milks in 1960. It is widely distributed in all biological fluids and is also expressed by immune cells, which release it under stimulation by pathogens
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_4
Started Jan 2018
Shorter than P25 for phase_4
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
October 30, 2018
CompletedFirst Submitted
Initial submission to the registry
February 5, 2020
CompletedFirst Posted
Study publicly available on registry
February 13, 2020
CompletedFebruary 13, 2020
February 1, 2020
Same day
February 5, 2020
February 10, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
comparison of efficacy of lactoferrin versus ferrous sulfate tharapy in treatment of patients with iron deficiency anemia.
Complete blood count will be done before and after therapy to detect the effect of the therapy on serum hemoglobin(g/d)
30 days
Comparison of efficacy of lactoferrin versus ferrous sulfate tharapy in treatment of patients with iron deficiency anemia.
Total serum iron(ug/d) will be done before and after therapy to detect effect of the therapy on total serum iron level (ug/d)
30 days
Study Arms (3)
lactoferrin
ACTIVE COMPARATOROral bovine lactoferrin (bfl) 100 mg once daily on empty stomach
ferrous sulfate
ACTIVE COMPARATOROral ferrous sulfate 3-6 mg/kg of elemental iron/day in divided doses
combined
ACTIVE COMPARATORcombined therapy (both lactoferrin and ferrous sulfate)
Interventions
Eligibility Criteria
You may not qualify if:
- Anemia rather than iron deficiency anemia.
- Family history of blood disease.
- Patients with thalassemia trait.
- Patients with chronic illness.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
AssuitU
Asyut, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ahmed Gaber Ahmed
Assiut University
Study Design
- Study Type
- interventional
- Phase
- phase 4
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- pediatrician
Study Record Dates
First Submitted
February 5, 2020
First Posted
February 13, 2020
Study Start
January 1, 2018
Primary Completion
January 1, 2018
Study Completion
October 30, 2018
Last Updated
February 13, 2020
Record last verified: 2020-02